+390677209020 | +39 0267380552 info@direnzo.biz | sedemilano@direnzo.biz | Italian Language

Herbals in medical devices: how to manage your products with MDCG 2022-5

Herbals in medical devices

In April 2022, the awaited guideline on borderline devices was published pursuant to Regulation 2017/745.

The document MDCG 2022-5, “Guidance on borderline between medical devices and medicinal products under Regulation (EU) 2017/745 on medical devices”, replaces MEDDEV 2.1/3 Rev3 (originally drafted to assist in the application of the requirements of Directive 93 /42/EEC on medical devices), and provides some clarifications on substance-based devices, with particular attention to the differences between the Directive and the Regulation, as well as the new requirements provided for by the Regulation.

Substance-based medical devices are products containing substances or mixes of substances, which act with mechanical/physical and not with a pharmacological, immunological, metabolic (PIM) mechanisms of action and which, therefore, cannot be classified as drugs.

These products, including creams, eye drops and nasal sprays, have been established on the market for several years as valid therapeutic options, often characterized by easy use and minor side effects.

The correct regulatory framework of the product

From the point of view of the correct regulatory framework of the product, MDCG 2022-5 represents an important step forward for the complete implementation of the Regulation.

The goal of the guideline is to clarify the definitions of “PIM” mechanism, and guide manufacturers to the correct classification of devices containing substances.

However, the guideline has a complex structure, whose real impact in the practice is still difficult to estimate.

Furthermore, it does not represent a legally binding document, but rather a document designed to support the implementation of the Regulation, the correct interpretation of which can only be delegated to the European Court of Justice.

To date, manufacturers of substance-based medical devices not only find themselves having to implement a whole series of new requirements introduced by the Regulation, but first of all they have re-evaluate the classification of their product as medical devices: the quality of a product as a medical device in fact represents the first step of the development process, even before classification, as well as an indispensable step to ensure compliance with the requirements of the Regulation.

It is important to remind that this preliminary phase is also necessary for devices already present on the market in accordance with the Directive (legacy devices), which may not be qualified as medical devices in accordance with the Regulation, despite having been so until now.

Substances of vegetable origin

The second chapter of the MDCG 2022-5 guideline deals, in particular, with substances of herbal origin, including the definitions of herbal medicinal product and traditional herbal medicinal product according to Directive 2001/83/EC.

This part is essential to fully understand the importance of herbal substances in healthcare, which represent one of the major challenges for the development of new treatments and remedies, with a strong impact on the market.

Any herbal substance present in the medical device, whether it is a herbal medicinal product or a traditional herbal medicinal product, always refers to the official monographs, when available: the EMA Committee on Herbal Medicinal Products (HMPC) is the official source of the monographs, however, there are others, which can be consulted if the substance of interest is not found in the EMA monograph.

If the mechanism of action is known and reported in the monograph, the manufacturer can only refer to the scientific literature to demonstrate that the substance does not act through a pharmacological, immunological or metabolic mechanism, thus justifying its presence in the device.

If, on the other hand, the mechanism of action is not fully known, or there is no monograph for the substance, its mechanism should be carefully examined and demonstrated by the manufacturer themselves.

Only after this preliminary activity, it will be possible to definitively decide whether the substance is, or is not, a medicine.

Therefore, it becomes essential for the manufacturer to investigate as much as possible, in particular by carrying out targeted pre-clinical tests that can demonstrate the mode of action of the substance or at least rule out a potential pharmacological mechanism.

This is undoubtedly a demanding challenge, especially if we consider that herbal substances, or complex mixtures of substances, act by virtue of the phytocomplex itself, with often unknown mechanisms.

This makes them very different from isolated substances, which act through specific and, above all, demonstrable mechanisms.

The mechanism of action of Herbals

The peculiar mechanism of action of herbals, that cannot be described by classical pharmacological models, represents a very important source of innovation in the field of health products, but at the same time it is also a big variable within the regulatory context of medical devices.

Today it is in fact impossible that one can identify each substance contained, for example, or each substance contained in an extract of chamomile, mallow or aloe.

Classic models would not work, excluding an important share of the market, the one of herbal substances in the devices, and above all, putting in a difficult position the manufacturing companies which have so far marketed eye drops, nasal sprays, soothing creams, i.e. all products commonly recognized as medical devices.

Therefore manufacturers, whether of a new device or of a legacy device, find themselves to manage an essential preliminary phase of the certification process, for which it is advisable to contact experts who consider all the aspects involved: regulatory as well as pharmacological and toxicological, including the need for pre-clinical testing.

At the same time, the concerned scientific sector is evolving together with the regulatory context. In fact, from a technological point of view, it is essential to identify new pre-clinical strategies for demonstrating the mechanisms of action, which go beyond the classic models, reducing animal testing and favouring in vitro models, 3Ds, reconstructed tissues.

From a regulatory point of view it is good to take into account the peculiar nature of herbals, substances within substances, which require a degree of specific demonstration calling into question the very nature of the device.

The greatest risk is that of having a large quantity of products on the market that cannot be classified either as drugs or as medical devices: in such a regulatory limbo, the product safety and quality would not be guaranteed to protect consumers.